Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;44(9):1042-1046.
doi: 10.1002/cac2.12578. Epub 2024 Jul 23.

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial

Jing Zuo  1 , Wei Duan  2 , Mingxuan Zhao  3 , Zhendong Chen  4 , Jie Lin  5 , Huaqiu Shi  6 , Ou Jiang  7 , Youzhong Zhang  8 , Meiyu Fang  9 , Li Wang  10 , Wei Wang  11 , Yong Huang  12 , Junyan Yu  13 , Xiaoxue Zhang  14 , Weiqing Pu  14 , Deshun Hao  14 , Fenglin She  14 , Xiugao Yang  14 , Ying Chen  14 , Qizhi Tang  14 , Xiao Zhang  14 , Miao Niu  14 , Yan'e Song  14 , Lingying Wu  1
Affiliations

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial

Jing Zuo et al. Cancer Commun (Lond). 2024 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Xiaoxue Zhang, Weiqing Pu, Deshun Hao, Fenglin She, Xiugao Yang, Ying Chen, Qizhi Tang, Xiao Zhang, Miao Niu, and Yan'e Song are employees of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. The others have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Characteristic of treatment response by IRC. (A) Timing and duration of responses in the EAS. The length of each bar represents the duration of treatment for each patient. (B) Best change from baseline in target lesion size in EAS. The dashed lines at −30% and +20% represent the cut‐offs for PR and PD. The Kaplan‐Meier curves of (C) PFS and (D) OS in the FAS. Kaplan‐Meier curves of PFS stratified by (E) liver metastasis versus non‐liver metastasis and (F) SCC versus non‐SCC. Abbreviations: CI, confidence interval; CR, complete response; EAS, efficacy analysis set; FAS, full analysis set; HR, hazard rate; IRC, Independent Review Committee; NA, not available; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SCC, squamous cell carcinoma; SD, stable disease.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
    1. Cheng M, Wang H, Zhao Y, Li G. Efficacy and Prognostic Factors for Response to PD‐1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study. Drug Des Dev Ther. 2022;16:887–897. - PMC - PubMed
    1. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira‐Frommer R, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856–1867. - PubMed
    1. Naumann RW, Hollebecque A, Meyer T, Devlin M‐J, Oaknin A, Kerger J, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019;37(31):2825–2834. - PMC - PubMed
    1. Chung HC, Ros W, Delord J‐P, Perets R, Italiano A, Shapira‐Frommer R, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE‐158 Study. J Clin Oncol. 2019;37(17):1470–1478. - PubMed

LinkOut - more resources